VKORC1 rs1384050: Understanding Warfarin Dosing Genetics
The rs1384050 variant is an intronic regulatory SNP located within the VKORC1 gene, which encodes the primary target of the anticoagulant medication warfarin. This variant is in high linkage disequilibrium with other well-studied markers, such as rs9923231, and is statistically associated with variations in the therapeutic dose required for patients.
What each genotype means
Higher warfarin dose requirement
This genotype is associated with higher VKORC1 expression and typically requires a higher maintenance dose of warfarin compared to carriers of the A allele. Because warfarin dosing is complex and influenced by multiple genetic and clinical factors, you should discuss your specific medication requirements with your clinician or pharmacist.
This genotype is common in populations of European ancestry and is the predominant genotype in many African populations.
Intermediate warfarin dose requirement
This genotype is associated with an intermediate sensitivity to warfarin, often requiring a lower dose than those with the GG genotype. Because warfarin dosing is complex and influenced by multiple genetic and clinical factors, you should discuss your specific medication requirements with your clinician or pharmacist.
This genotype is frequently observed in individuals of European and mixed ancestry.
Lower warfarin dose requirement
This genotype is associated with lower VKORC1 expression and increased sensitivity to warfarin, which typically necessitates a lower maintenance dose to avoid bleeding risks. Because warfarin dosing is complex and influenced by multiple genetic and clinical factors, you should discuss your specific medication requirements with your clinician or pharmacist.
This genotype is highly prevalent in East Asian populations and is also found at significant frequencies in European populations.
What is rs1384050 and Where is it Located?
The rs1384050 variant is a single nucleotide polymorphism (SNP) situated within the VKORC1 gene on chromosome 16. In genomics, an intronic variant like this resides in a non-coding region of the gene, yet it can still exert significant influence on gene expression and regulation. This specific SNP is recognized for its high linkage disequilibrium with other nearby variants, most notably rs9923231, which is widely documented in pharmacogenomic literature. Because these variants are inherited together as a block, rs1384050 often serves as a proxy for the functional genetic landscape of the VKORC1 locus. Understanding its location is essential for researchers studying how genetic architecture influences the body's response to specific drugs, particularly those that target the vitamin K cycle.
The Role of the VKORC1 Gene
The VKORC1 gene provides instructions for creating the vitamin K epoxide reductase complex subunit 1 enzyme. This enzyme is a critical component of the vitamin K cycle, a biological process necessary for the production of functional blood-clotting factors. Warfarin, a common anticoagulant, works by inhibiting this enzyme, thereby reducing the body's ability to form clots. Because VKORC1 is the direct target of warfarin, any genetic variation that alters the expression or efficiency of this enzyme can change how sensitive a person is to the drug. Individuals with certain genetic profiles may produce less of the enzyme, making them more sensitive to warfarin and requiring lower doses to achieve the same therapeutic effect, while others may require higher doses.
Research Associations and Evidence Strength
Research into VKORC1 variants has established them as primary genetic determinants of warfarin dose requirements. While rs1384050 is frequently studied due to its linkage with the functional promoter variant rs9923231, the evidence strength for rs1384050 specifically is often categorized as limited compared to its more famous neighbors. Clinical studies consistently show that patients carrying specific alleles at the VKORC1 locus require significantly different maintenance doses of warfarin to avoid the risks of either ineffective anticoagulation or severe bleeding. However, it is important to note that warfarin dosing is multifactorial; it is influenced not only by genetics (including other genes like CYP2C9) but also by clinical factors such as age, body weight, and concurrent medications. Genetic testing is one tool among many used by clinicians to optimize therapy.
Population Frequency and Diversity
The frequency of VKORC1 variants varies significantly across different ancestral populations, which contributes to observed differences in warfarin sensitivity globally. For the broader VKORC1 locus, the minor allele frequency (MAF) is approximately 0.35 to 0.40 in European populations, while it is much higher in East Asian populations (approximately 0.85) and lower in African populations (approximately 0.10). These differences in allele frequency help explain why average warfarin dose requirements can differ between ethnic groups. Because these variants are so common in certain populations, they are considered major contributors to the inter-individual variability in drug response. Researchers emphasize that these frequency differences are a key reason why pharmacogenomic guidelines must be interpreted within the context of a patient's specific genetic background.
What You Can and Cannot Do With This Information
Genetic information regarding VKORC1 can provide valuable insights into why individuals respond differently to warfarin, but it is not a substitute for professional medical judgment. You cannot use this information to self-diagnose or adjust your medication dosage. If you have received genetic testing results, the most important step is to discuss them with your physician or a clinical pharmacist. They are trained to integrate your genetic data with your clinical history, current health status, and other medications to determine the safest and most effective treatment plan. Never stop or change your warfarin dose based on genetic reports alone, as doing so could lead to serious health complications. Always rely on your healthcare team to manage your anticoagulation therapy.
How common is this variant?
The frequency of VKORC1 variants is highly ancestry-dependent, with the minor allele frequency ranging from approximately 0.10 in African populations to 0.85 in East Asian populations.
Frequently asked questions
Does my VKORC1 genotype mean I cannot take warfarin?
No, having a specific VKORC1 genotype does not mean you cannot take warfarin. It simply means your doctor may need to adjust your starting dose to ensure you reach the correct level of anticoagulation safely.
Is a genetic test for VKORC1 required before starting warfarin?
While genetic testing can help predict dose requirements, it is not universally required for every patient. Your doctor will decide if testing is appropriate based on your specific clinical situation and local medical guidelines.
Are there other genes that affect warfarin besides VKORC1?
Yes, the CYP2C9 gene is also a major factor in how the body metabolizes warfarin. Clinicians often consider both VKORC1 and CYP2C9 genotypes when calculating an initial dose.
Can I change my warfarin dose based on my SNP results?
Absolutely not. You should never change your medication dose without consulting your doctor, as incorrect dosing can lead to dangerous blood clots or severe bleeding.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1384050?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VKORC1
The VKORC1 -1639G>A promoter variant reduces vitamin K epoxide reductase subunit 1 expression, requiring lower therapeutic warfarin maintenance doses to prevent bleeding complications.
This VKORC1 variant is a clinically useful marker for sensitivity to warfarin and related vitamin-K-antagonist dosing, with direct implications for medication safety.
Promoter variant in VKORC1 influencing warfarin sensitivity and dosing requirements.
Regulatory variant in the VKORC1 promoter region that significantly influences warfarin dose requirements.
Located in VKORC1, this missense variant (p.Val66Met) is associated with warfarin resistance requiring elevated therapeutic dosages.
This variant is a well-established marker in the VKORC1 gene often used in studies regarding warfarin sensitivity and dosing.